Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022